Article
Radiology, Nuclear Medicine & Medical Imaging
Julie Dewaguet, Marie-Christine Copin, Alain Duhamel, Jean-Baptiste Faivre, Valerie Deken, Martin Sedlmair, Thomas Flohr, Bernhard Schmidt, Alexis Cortot, Eric Wasielewski, Jacques Remy, Martine Remy-Jardin
Summary: This study focused on the perfusion analysis of non-small cell lung cancers using dual-phase, dual-energy CT. The results showed higher perfusion between the tumor edge and lung parenchyma in hypoxic tumors, and functional characteristics of neovascularization were found in mCA IX-positive tumors.
Article
Environmental Sciences
Peng Qiu, Yutao Chen, Cheng Dong, Juanjuan Xie, Junwu Wang
Summary: This study analyzed scRNA-seq data of LUAD patients to identify DEGs associated with immune infiltration and survival time, and predicted transcriptional factors. The findings shed new light on the molecular mechanisms and potential individual therapy of LUAD.
ENVIRONMENTAL TOXICOLOGY
(2023)
Article
Oncology
Alessandro La Ferlita, Rosario Distefano, Salvatore Alaimo, Joal D. Beane, Alfredo Ferro, Carlo M. Croce, Philip N. Tsichlis, Alfredo Pulvirenti, Giovanni Nigita
Summary: Lung cancer is the second most common cancer worldwide, and lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the most common subtypes. This study characterized the expression of human endogenous retroviruses (HERVs) at genomic locus-specific resolution in lung cancer and found dysregulated HERVs. The findings may contribute to the identification of novel biomarkers for lung cancer.
Article
Biochemistry & Molecular Biology
Margarita Pustovalova, Philipp Malakhov, Anastasia Guryanova, Maxim Sorokin, Maria Suntsova, Anton Buzdin, Andreyan N. N. Osipov, Sergey Leonov
Summary: Radioresistance is a major obstacle in the successful therapy of many cancers, including non-small cell lung cancer (NSCLC). By comparing the transcriptional changes of radioresistant NSCLC cells with parental cells using RNA-seq, differentially expressed genes associated with radioresistance were identified. These gene expressions reflect the complex biological processes involved in clinical cancer cell eradication and might serve as potential biomarkers and therapeutic targets for NSCLC treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Zeng-Hong Wu, Cheng Li, You-Jing Zhang, Rong Lin
Summary: This study identified atypical signature exosomes for hepatocellular carcinoma (HCC) based on analyses of exosome and online databases, providing potential biomarkers for HCC treatment.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Juan Wu, Ru Chen, Huiqing Shen, Ting Yan, Yu Qian, Yaping Zhang, Zhuoya Huang, Pengzhou Kong, Min Pang, Xinri Zhang
Summary: The study showed that ivosidenib can inhibit the proliferation, invasion, and migration of NSCLC cells, as well as suppress tumor growth in vivo, by regulating the interactions between mRNA and ncRNA. Additionally, DE-mRNAs in ivosidenib-treated NSCLC cells were significantly enriched in several cancer-associated pathways, including the TGF-beta signaling pathway and PI3K-Akt signaling pathway.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biotechnology & Applied Microbiology
Min Soo Joo, Kyoung-Ho Pyo, Jong-Moon Chung, Byoung Chul Cho
Summary: This paper investigates statistical techniques and AI-based methods for analyzing non-small cell lung cancer transcriptome data. The goal is to find essential biomarkers and classify carcinomas and cluster NSCLC subtypes. The methods are divided into three categories: statistical analysis, machine learning, and deep learning. The paper summarizes specific models and ensemble techniques used in NSCLC analysis, aiming to lay a foundation for advanced research by converging and linking the various analysis methods available.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Ru Chen, Juan Wu, Chang Lu, Ting Yan, Yu Qian, Huiqing Shen, Yujing Zhao, Jianzhen Wang, Pengzhou Kong, Xinri Zhang
Summary: CA extracted from cinnamon has shown antiviral and anti-tumor effects, including inhibiting proliferation, invasion, and migration, inducing apoptosis, and suppressing tumor growth in NSCLC. Through the ceRNA network, key genes SOCS1, BTG2, and BTK were identified as playing essential roles in CA against NSCLC.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Kamila Baran, Jacek Kordiak, Slawomir Jablonski, Ewa Brzezianska-Lasota
Summary: This study evaluated the expression levels of CCR6/CCL20 mRNA and non-coding RNAs (ncRNAs) such as miR-150 and linc00673 in NSCLC tissue. It was found that CCL20 mRNA was upregulated while CCR6 mRNA was downregulated in tumor tissue. In addition, the expression levels of miR-150 and linc00673 in serum extracellular vesicles showed associations with tumor staging and histopathological type.
SCIENTIFIC REPORTS
(2023)
Review
Biochemistry & Molecular Biology
Agnieszka Rybarczyk-Kasiuchnicz, Rodryg Ramlau, Katarzyna Stencel
Summary: Lung cancer is a common malignant neoplasm that may progress to metastasize to the central nervous system, affecting the prognosis unfavorably. The discovery of EGFR-activating mutations and ALK rearrangements in lung adenocarcinoma patients has led to the introduction of small-molecule tyrosine kinase inhibitors for advanced-stage treatment. These inhibitors target different pathways to improve progression-free survival in patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Akshay J. Patel, Naeem Khan, Alex Richter, Babu Naidu, Mark T. Drayson, Gary W. Middleton
Summary: B cells play a key role in lung cancer pathogenesis and response to immunotherapy. The B cell repertoire differs between tumor and circulation, with a diverse range of plasma cell and memory cell phenotypes in lung cancer. The influence of smoking and tumor type on the B cell repertoire is limited.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, Research & Experimental
Jin Chen, Zhongqiu Wu, Wenyi Deng, Minying Tang, Lvying Wu, Na Lin, Liuyan Chen, Yunfeng Fu, Min Zhao, Changguo Chen, Wenting Li
Summary: USP51 regulates TWIST1 protein through deubiquitination, influencing stemness and growth of non-small cell lung carcinoma (NSCLC) cells.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Review
Oncology
Justyna Raczkowska, Agnieszka Bielska, Adam Kretowski, Magdalena Niemira
Summary: Non-small cell lung cancer (NSCLC) is a malignant condition resistant to advanced-stage treatment and the leading cause of cancer death worldwide. Current diagnostic methods cannot detect the disease at an early stage or predict its development. Micro RNAs (miRNAs) show significant differences in NSCLC tissues and can be easily detected in biofluids without invasive collection techniques. Many studies support the importance of miRNAs as a promising biomarker for detecting and predicting NSCLC. This review discusses the role of biofluid miRNAs as a diagnostic tool in NSCLC and highlights future areas of interest.
FRONTIERS IN ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Balazs Gyorffy
Summary: This study established a comprehensive database of transcriptome-level data for lung cancer, which can be used to identify and rank the most promising biomarkers and therapeutic targets for different subtypes of lung cancer.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Takuya Matsui, Noriaki Sakakura, Shin Koyama, Keita Nakanishi, Eiichi Sasaki, Seiichi Kato, Waki Hosoda, Yoshiko Murakami, Hiroaki Kuroda, Yasushi Yatabe
Summary: Invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive lung adenocarcinoma with differences in lymph node metastasis and KRAS mutations compared to non-IMA. Patients with IMA have a higher rate of intrapulmonary recurrence postoperatively, leading to significantly worse prognosis among those with lung recurrence compared to non-IMA patients. Overall survival rates at 5 years did not differ significantly between the two groups.
ANNALS OF THORACIC SURGERY
(2021)
Article
Genetics & Heredity
Ryan Sun, Miao Xu, Xihao Li, Sheila Gaynor, Hufeng Zhou, Zilin Li, Yohan Bosse, Stephen Lam, Ming-Sound Tsao, Adonina Tardon, Chu Chen, Jennifer Doherty, Gary Goodman, Stig E. Bojesen, Maria T. Landi, Mattias Johansson, John K. Field, Heike Bickeboeller, H-Erich Wichmann, Angela Risch, Gadi Rennert, Suzanne Arnold, Xifeng Wu, Olle Melander, Hans Brunnstrom, Loic Le Marchand, Geoffrey Liu, Angeline Andrew, Eric Duell, Lambertus A. Kiemeney, Hongbing Shen, Aage Haugen, Mikael Johansson, Kjell Grankvist, Neil Caporaso, Penella Woll, M. Dawn Teare, Ghislaine Scelo, Yun-Chul Hong, Jian-Min Yuan, Philip Lazarus, Matthew B. Schabath, Melinda C. Aldrich, Demetrios Albanes, Raymond Mak, David Barbie, Paul Brennan, Rayjean J. Hung, Christopher I. Amos, David C. Christiani, Xihong Lin
Summary: This study prioritizes and characterizes single nucleotide polymorphisms (SNPs) that increase the risk of squamous cell lung cancer by utilizing extensive multiomics data sources and genome-wide functional annotations. The reanalysis of data highlights the impact of SNPs from nuclear factor-kappa B signaling pathway genes and major histocompatibility complex-mediated immune responses on lung cancer. The strategies introduced in this study provide informative and systematic approaches for incorporating genome-wide annotation data in genetic association studies.
GENETIC EPIDEMIOLOGY
(2021)
Article
Multidisciplinary Sciences
Nhu-An Pham, Nikolina Radulovich, Emin Ibrahimov, Sebastiao N. Martins-Filho, Quan Li, Melania Pintilie, Jessica Weiss, Vibha Raghavan, Michael Cabanero, Robert E. Denroche, Julie M. Wilson, Cristiane Metran-Nascente, Ayelet Borgida, Shawn Hutchinson, Anna Dodd, Michael Begora, Dianne Chadwick, Stefano Serra, Jennifer J. Knox, Steven Gallinger, David W. Hedley, Lakshmi Muthuswamy, Ming-Sound Tsao
Summary: Patient-derived xenograft (PDX) and xenograft-derived organoid (XDO) models play a crucial role in recapitulating the genotypic and phenotypic landscape of patient cancers, specifically pancreatic ductal adenocarcinoma (PDAC). These models have shown promise in advancing research, molecular profiling of tumor models, and evaluating novel drug combination therapies.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Masashi Mikubo, Yoshiaki Inoue, Geoffrey Liu, Ming-Sound Tsao
Summary: A minor population of cancer cells can evade cell death from chemotherapy and targeted therapy by entering a reversible slow proliferation state known as the drug tolerant persister (DTP) state. Understanding the biology of DTP cells and developing therapeutic strategies targeting this mechanism can have significant clinical implications in overcoming cancer persistence. Emerging evidence suggests that DTP cells adapt to new environments through epigenomic modification, transcriptomic regulation, flexible energy metabolism, and interactions with the tumor microenvironment.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Sally C. M. Lau, Christopher Poletes, Lisa W. Le, Kate M. Mackay, Aline Fusco Fares, Penelope A. Bradbury, Frances A. Shepherd, Ming Sound Tsao, Natasha B. Leighl, Geoffrey Liu, David Shultz, Adrian G. Sacher
Summary: ICIs show remarkable efficacy in the treatment of brain metastases in patients with EGFR/ALK wild-type mNSCLC, providing effective disease control. Baseline radiation plus ICIs can be considered as an effective strategy for patients with PD-L1 50% and further investigation is warranted to delay whole brain radiation therapy in this subgroup of patients.
Article
Oncology
Charu Aggarwal, Lukas Bubendorf, Wendy A. Cooper, Peter Illei, Paula Borralho Nunes, Boon-Hean Ong, Ming-Sound Tsao, Yasushi Yatabe, Keith M. Kerr
Summary: Precision medicine in non-small cell lung cancer (NSCLC) is rapidly advancing, with targeted therapies for advanced disease being developed and molecular testing becoming increasingly important. While routine molecular testing is not currently required for stage I-III disease, recent studies have shown promising results that suggest the integration of molecular testing and targeted therapy may be beneficial for these earlier stages of NSCLC in the near future.
Editorial Material
Oncology
Ming-Sound Tsao, Andrew G. Nicholson, Joseph J. Maleszewski, Alexander Marx, William D. Travis
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Ku-Geng Huo, Hirotsugu Notsuda, Zhenhao Fang, Ningdi Feng Liu, Teklab Gebregiworgis, Quan Li, Nhu-An Pham, Ming Li, Ni Liu, Frances A. Shepherd, Christopher B. Marshall, Mitsuhiko Ikura, Nadeem Moghal, Ming-Sound Tsao
Summary: This study found that clinically approved EGFR TKIs can be used to treat patients with non-small cell lung cancer harboring the BRAF(G469V) mutation. Through experiments with a xenograft model and a cell line, it was confirmed that BRAF G469v is the oncogenic driver in this mutation. Structural modeling and experiments further demonstrated that BRAF(G469V) is a direct target of EGFR TKIs.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Teklab Gebregiworgis, Yoshihito Kano, Jonathan St-Germain, Nikolina Radulovich, Molly L. Udaskin, Ahmet Mentes, Richard Huang, Betty P. K. Poon, Wenguang He, Ivette Valencia-Sama, Claire M. Robinson, Melissa Huestis, Jinmin Miao, Jen Jen Yeh, Zhong-Yin Zhang, Meredith S. Irwin, Jeffrey E. Lee, Ming-Sound Tsao, Brian Raught, Christopher B. Marshall, Michael Ohh, Mitsuhiko Ikura
Summary: This study demonstrates that KRAS Q61H mutation is not regulated by SHP2, leading to insensitivity to SHP2 inhibitors in pancreatic cancer cells. Furthermore, cancer cells with different KRAS mutations exhibit variable sensitivity to SHP2 inhibitors, potentially due to differences in regulation by GAP and GEF activities, as well as binding affinity to RAF.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Dalam Ly, Quan Li, Roya Navab, Cedric Zeltz, Linan Fang, Michael Cabanero, Chang-Qi Zhu, Ming-Sound Tsao, Li Zhang
Summary: Understanding how the immune system regulates the tumor microenvironment is crucial for the development of effective cancer treatments. This study reveals the adverse prognostic role of LAIR2 expression in regulatory T cells and identifies it as a potential target for future immunotherapies.
Article
Biochemistry & Molecular Biology
Cedric Zeltz, Maryam Khalil, Roya Navab, Ming-Sound Tsao
Summary: Collagen type XI restrains collagen remodeling and cell migration mediated by cancer-associated fibroblasts (CAF), thereby limiting the invasion of lung cancer cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Joshua C. Rosen, Adrian Sacher, Ming-Sound Tsao
Summary: KRAS(G12C) inhibitors have shown promising results in clinical trials with overall response rates ranging between 32% and 46%, and have been granted FDA approvals as second-line or later monotherapies. However, rapid tumor resistance complicates their use as a monotherapy.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Shelley Kuang, Andrea S. Fung, Kirstin A. Perdrizet, Kaitlin Chen, Janice J. N. Li, Lisa W. Le, Michael Cabanero, Ola Abu Al Karsaneh, Ming S. Tsao, Josh Morganstein, Laura Ranich, Adam C. Smith, Cuihong Wei, Carol Cheung, Frances A. Shepherd, Geoffrey Liu, Penelope Bradbury, Prodipto Pal, Joerg Schwock, Adrian G. Sacher, Jennifer H. Law, Tracy L. Stockley, Natasha B. Leighl
Summary: In NSCLC patients, reflex testing using NGS panels can identify actionable genetic variants in the majority of cases with minimal increase in testing cost. Implementation of NGS panels is essential for the treatment of NSCLC patients as treatment paradigms continue to evolve.
Meeting Abstract
Medicine, Research & Experimental
Ellen Yang, Najd Alshamlan, Jessica Weiss, Michael Cabanero, Ming Tsao
LABORATORY INVESTIGATION
(2022)
Meeting Abstract
Immunology
Wenxi Xu, Laura M. Snell, Mengdi Guo, Giselle Boukhaled, Bethany L. Macleod, Ming Li, Michael V. Tullius, Cynthia J. Guidos, Ming-Sound Tsao, Maziar Divangahi, Marcus A. Horwitz, Jun Liu, David G. Brooks
JOURNAL OF IMMUNOLOGY
(2021)
Review
Oncology
Barbara Melosky, Parneet Cheema, Rosalyn A. Juergens, Natasha B. Leighl, Geoffrey Liu, Paul Wheatley-Price, Adrian Sacher, Stephanie Snow, Ming-Sound Tsao, Deanna McLeod, Quincy Chu
Summary: Adjuvant treatment with EGFR inhibitors in early NSCLC has shown varying efficacy, but osimertinib has emerged as an important new option for stage II-IIIA EGFR-mutated NSCLC.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)